

1 **Inferred duration of infectious period of SARS-CoV-2: rapid scoping review**
2 **and analysis of available evidence for asymptomatic and symptomatic**
3 **COVID-19 cases**

4 **Andrew W. Byrne¹, David McEvoy², Áine B. Collins³, Kevin Hunt⁴, Miriam Casey³, Ann Barber³,**
5 **Francis Butler⁴, John Griffin⁶, Elizabeth A. Lane⁶, Conor McAloon⁵, Kirsty O'Brien⁷, Patrick Wall²,**
6 **Kieran A. Walsh⁷, Simon J. More³**

7 ¹ One-Health Scientific Support Unit, DAFM, Government of Ireland, Kildare Street, Dublin 2, Ireland.
8 <https://orcid.org/0000-0003-0296-4586>

9 ² School of Public Health, Physiotherapy, and Sports Science, University College Dublin, Belfield,
10 Dublin 4, Ireland.

11 ³ Centre for Veterinary Epidemiology and Risk Analysis, School of Veterinary Medicine, University
12 College Dublin, Belfield, Dublin 4, Ireland.

13 ⁴ School of Biosystems and Food Engineering, University College Dublin, Belfield, Dublin 4, Ireland.

14 ⁵ School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland.

15 ⁶ Department of Agriculture, Food and the Marine, Government of Ireland, Kildare Street, Dublin 2,
16 Ireland.

17 ⁷ Health Information and Quality Authority (HIQA), Unit 1301, City Gate, Cork, Ireland.

18 **Abstract**

19 **Objectives:** Our objective was to review the literature on the inferred duration of the infectious
20 period of COVID-19, caused by SARS-COV-2 virus, and provide an overview of the variation
21 depending on the methodological approach.

22 **Design:** Rapid scoping review. Literature review with fixed search terms, up to 1st April 2020. Central
23 tendency and variation of the parameter estimates for infectious period in (a) asymptomatic (b)
24 symptomatic cases from (i) virological studies (repeated testing), (ii) tracing studies (iii) modelling
25 studies were gathered. Narrative review of viral dynamics.

26 **Information sources:** Search strategies developed and the following searched: PubMed, Google
27 Scholar, MedRxiv, BioRxiv. Additionally, the Health Information Quality Authority (Ireland) viral load
28 synthesis was utilised, which screened literature from PubMed, Embase, ScienceDirect, NHS
29 evidence, Cochrane, medRxiv and bioRxiv, HRB open databases.

30 **Results:** There was substantial variation in the estimates, and how infectious period was inferred.
31 One study provided approximate median infectious period for asymptomatic cases of 6.5-9.5 days.
32 Median pre-symptomatic infectious period across studies varied over <1-4 days. Estimated mean
33 time from symptom onset to two negative RT-PCR tests was 13.4 days (95%CI: 10.9-15.8), but was
34 shorter when studies included children or less severe cases. Estimated mean duration from
35 symptom onset to hospital discharge or death (potential maximal infectious period) was 18.1 days
36 (95%CI: 15.1–21.0); time to discharge was on average 4 days shorter than time-to-death. Viral
37 dynamic data and model infectious parameters were often shorter than repeated diagnostic data.

38 **Conclusions:** There are limitations of inferring infectiousness from repeated diagnosis, viral loads,
39 and viral replication data alone, and also potential patient recall bias relevant to estimating exposure
40 and symptom onset times. Despite this, available data provides a preliminary evidence base to
41 inform models of central tendency for key parameters, and variation for exploring parameter space
42 and sensitivity analysis. Some current models may be underestimating infectious period.

43 **Introduction**

44 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a new coronavirus, emerged in
45 China in late 2019.[1,2] The virus causes COVID-19, a disease characterized by variable, mainly
46 respiratory, symptoms across cohorts, from asymptomatic cases through to mild (for example, dry
47 cough, fever) and severe cases (for example, pneumonia).[3,4] The severity of symptoms, and their
48 clinical outcome, have been reported to vary by age-class and whether patients have underlying
49 comorbidities. The case-fatality rate increases with age, and are highest for those above 70
50 years.[5,6] There are several cases of asymptomatic test-positive patients reported in the emerging
51 literature (e.g. [4,7,8]). Furthermore, asymptomatic (and pre-symptomatic) cases have been shown
52 to be infectious, and secondary cases have been reported.[9,10] However, the duration of this
53 infectious period is difficult to measure accurately, and the time course of the natural history of
54 infection generally must be inferred indirectly, via contact tracing of cases, serial repeated diagnostic
55 virological studies, and/or through modelling approaches. Symptomatic cases can experience an
56 infectious pre-symptomatic period before the onset of symptoms, therefore understanding the
57 whole infectious period for this cohort requires estimating the duration of both periods. It is
58 essential to rapidly gain insight into this key variable impacting our understanding of COVID-19
59 epidemiology. Anderson et al. [11] point out one of the “key unknowns” is the infectious period for
60 COVID-19, which they suggest may be 10 days but subject to great uncertainty.

61 Here we gathered data from published research from peer-reviewed and preprints from 1st
62 December to 1st April 2020, to characterize the variation in the infectious duration inferred from the
63 three lines of evidence. We also provide a narrative review of the viral dynamic literature. Our focus
64 was on duration, relative infectiousness has been dealt with elsewhere [12,13]

65 The aim of this review was to provide an overview and critical appraisal of published and preprint
66 articles and reports that assess or quantify the inferred duration of the infectious period in order to
67 best parameterise COVID-19 epidemiological transmission models.

68 **Materials and Methods**

69 ***Conceptual model of population infection dynamics***

70 Infectious period was contextualised in relation to a working conceptual model of COVID-19 disease
71 dynamics (Figure S1). From this conceptual model, three parameters were identified as important in
72 context of this study:

73 T2, defined as: Duration of the total infectious period for asymptomatic cases, post-latent to
74 recovery [‘recover’ in this context relates to clearing of infection]

75 T3, defined as: Duration of pre-symptomatic infectious period for those infected individuals
76 who subsequently develop symptoms (that is, post-latent to onset of symptoms)

77 T5, defined as: Duration from onset of symptoms to recovery* or death.

78 * recovery was inferred as either the first of two clear RT-PCR tests, or hospital discharge after
79 admission from COVID-19 related symptoms.

80 “Asymptomatic” case definition was interpreted pragmatically following Davies et al. [14,15], and
81 may include very mild symptoms that may occur but are unnoticed.

82 T2, T3, T5 represent readily measurable parameters, but may be upper limits of infectious period, as
83 patients may be non-infectious for a period before recovery or death. We also review evidence
84 where infectiousness is inferred from viral shedding and contact tracing [transmission], see below.

85 ***Literature search***

86 A survey of the literature between 1st December 2019 and 1st April 2020 for all countries was
87 implemented using the following search strategy. Publications on the electronic databases PubMed,
88 Google Scholar, MedRxiv and BioRxiv were searched with the following keywords: “Novel
89 coronavirus” OR “SARS-CoV-2” OR “2019-nCoV” OR “COVID-19” AND “infectious”. Additionally,
90 national and international government reports were monitored. No restrictions on language or
91 publication status were imposed so long as an English abstract was available. Articles were evaluated
92 for data relating to the aim of this review; all relevant publications were considered for possible
93 inclusion. Bibliographies within these publications were also searched for additional resources.

94 Manual searches of the literature was undertaken using daily updated COVID19 collections
95 from the National Centre for Biotechnology Information (NCBI) and MedRxiv servers
96 (<https://connect.medrxiv.org/relate/content/181>), respectively, searching specifically for
97 papers relating to “infectious period” or “infectious duration” from both empirical and
98 modelling studies.

99 Finally, we utilised the complementary work undertaken by the Health Information and Quality
100 Authority (HIQA) of Ireland, specifically the evidence summaries relating to asymptomatic
101 transmission and viral load [16,17]. The protocol for the evidence synthesis is published on the HIQA
102 website [18]. Briefly, the evidence synthesis process included searching databases from 30th

103 December 2019 to 27th March 2020 (PubMed, Embase, ScienceDirect, NHS evidence, Cochrane,
104 medRxiv and bioRxiv, HRB open), screening, data extraction, critical appraisal and summarizing the
105 evidence.

106 Our aim was to have as great a breadth for an evidential base as possible, to clarify what evidence
107 was available to inform on the infectious period of COVID19, and to identify key characteristics of
108 the data sources and their interpretation. Therefore, our approach is a scoping review (following
109 [19]). However, due to the emergent nature of COVID-19, this work is considered a rapid review.[20]
110 This paper follows the Preferred Reporting Items for Systematic Reviews and Meta-Analyses—
111 Extension for Scoping Reviews (PRISMA-ScR) checklist.

112

113 Inclusion criteria were for papers that provided data to inform duration of infectious period based
114 on: time from symptoms to recovery; time from symptoms to death; time from symptoms to
115 diagnostic test clearance [\geq two clear tests, defined as at least two consecutive negative reverse
116 transcriptase polymerase chain reaction (RT-PCR) tests conducted 24 hours apart]; pre-symptomatic
117 infectious period; time from first diagnostic test to diagnostic test clearance [\geq two clear tests] for
118 pre-symptomatic/asymptomatic cases. Inclusion criteria for viral dynamics, were papers which
119 reported viral load via cycle threshold (Ct) values from RT-PCR testing over repeated sampling of
120 infected patients, and studies that additionally reported viral isolation.

121 For quality control, studies were (i) selected and screened initially by three members of the team
122 from search terms outlined above (*ÁBC, KH, FB*), with parameters identified and recorded. (ii) This
123 was reviewed and supplemented by manual search by a different two team members (*AWB, DM*),
124 again with parameters identified and recorded. (iii) Finally, the review was then internally reviewed
125 by an additional two members of the team (*CMc, MC*), and cross-referenced with other parameter
126 synthesis documents being worked on by the group (*all authors*).

127 ***Parameter comparison***

128 *Parameters of interest*

129 1. *A-priori* it was decided to harvest parameter estimates for (i) asymptomatic, and (ii)
130 symptomatic cases. As the period of infectiousness can only be estimated indirectly,
131 parameter estimates from the literature was gathered from three different methodological
132 approaches: Virological studies tracking patients overtime undertaking serial testing, where
133 infectious period was inferred from diagnostic testing history and/or by virus isolation.

- 134 2. Contact tracing studies where infectiousness is inferred by infector-infectee histories and/or
135 clusters of infection.
- 136 3. Model parameters entered into mathematical models [priors] representing explicitly
137 infectious periods, or model parameters estimated from mathematical models [posterior
138 estimates] estimating explicitly infectious periods

139

140 Visual and quantitative comparisons

141 To compare parameters visually, simulated distributions were estimated from the central tendencies
142 and variation metrics described in the primary literature. To simulate data, 10,000 random variates
143 were drawn from random number functions in Stata (ME, version 15.1; StataCorp. 2017. Stata
144 Statistical Software: Release 15. College Station, TX: StataCorp LLC) [rnormal, rgamma]. Where
145 possible, the distribution reported within the primary literature was used to represent the
146 distribution (e.g. Gaussian, Gamma). Where distributional data could not be inferred, point
147 estimates were presented.

148 There were adequate comparable data gathered on the duration of T5 (duration from onset of
149 symptoms to death or recovery) from virological studies to employ a meta-analytic model. Many of
150 the studies report different central tendency estimates, including mean and median. Variation
151 across this central tendencies included standard deviation, range, inter-quartile range. To allow for
152 meta-analytic comparison, the mean and standard deviations were derived for each parameter given
153 the available central tendency and variation reported in studies based on the formulae given in Wan
154 et al. [21].

155 To obtain the standard deviations from 95%CI, the method outlined in the Cochrane handbook [22]
156 was used:

$$157 \text{SD: } \sqrt{n}(\text{Upper limit of CI} - \text{Lower limit of CI})/3.92$$

158

159 Standard Error (SE) was calculated from Standard Deviation (SD) and sample size (n), using:

$$160 \text{SE} = \text{SD}/\text{SQRT}(n)$$

161 Comparisons were made using the METAAN package in Stata 15, using the random-effects
162 (DerSimonian-Laird) model.[23] This model assumes heterogeneity between the studies; that is, it
163 assumes that the true effect can be different for each study. The model assumes that the individual-
164 study true effects are distributed with a variance τ^2 around an overall true effect, but the model

165 makes no assumptions about the form of the distribution of either the within-study or the between-
166 studies effects. Weightings were derived from the standard error [precision] around the estimate.
167 Comparisons were presented as forest plots. Heterogeneity between studies was tested using
168 Cochrane's Q; the magnitude of the heterogeneity was categorised using i^2 as high (>75%), moderate
169 (50-75%), or low (<50%).[24]

170 Variation in duration across T5 virological studies was compared using a random effects meta-
171 regression model, using the METAREG command in Stata 15.1. The hypothesis that heterogeneity
172 may be related to the inclusion of children or depending on symptom severity within the sample,
173 was tested in separate univariate models. Severity was dichotomised (0/1) into studies that included
174 patients described as having 'mild' or 'mild-moderate' symptoms, versus studies that included
175 patients with 'moderate-severe' or 'severe' symptoms. Similarly, studies were categorised into
176 having some samples from "children" (as reported in the paper), or wholly adult samples. These
177 variables were then fitted as a dichotomous dummy predictor [independent] variables. The
178 parameter estimates from the regression model was solved using restricted maximum likelihood
179 (REML); additionally, p-values were estimated using a Monte Carlo model with 1000 permutation
180 test.[25]

181 Raw patient-level data were available from three studies in relation to time from onset to hospital
182 discharge or death (potentially inferring maximal T5 duration). To estimate the predicted mean and
183 95%CI duration across these studies, data were analysed using a Gaussian random effects model
184 (using XTREG command, Stata 15), with study categories fitted as the RE. A linear regression model
185 with 'study' fitted as a categorical dummy variable was used to estimate the difference between
186 duration across study datasets. Code and data are provided in supplementary material.

187 ***Viral dynamics***

188 A narrative comparison of reported viral dynamics from studies that undertook serial viral load
189 estimates from patients over their period of observation was undertaken. Trends in the literature,
190 strength and weaknesses were identified, and a conceptual model illustrated.

191 **Results**

192 ***Parameter comparison***

193 Overall, 65 parameter estimates were harvested from 48 papers (Tables 1, 2, 3).

194 *Infectious period for asymptomatic cases (T2)*

195 The overall distributions and point estimates from studies for T2 are presented in Figure 1 and Table
196 1.

197 Two virological studies reported on infectious period based on serial diagnostic testing, for
198 asymptomatic cases, were found to have informative data. One of these studies reported on only
199 one asymptomatic case, with exposure to negative tests being 11 days (Zhou et al, 2020). This
200 duration should be considered an over-estimate, given that a latent period is not taken into
201 consideration. Hu et al. [7] tracked infections of close contacts to infected persons and considered
202 patients asymptomatic at time of diagnosis. Infectious period was defined as time from diagnosis to
203 the first of two clear tests, providing a median duration of 9.5 days (n=24) range: 1 – 21; 3.5-13.0
204 IQR.

205 Importantly, Hu et al. [7] found that the infectious period was different between those who
206 subsequently exhibited symptoms (i.e. pre-symptomatic) and those who did not: The median
207 duration for asymptomatic infectious was 6.0 days (IQR: 2.0 - 12.0; N=19). This was reduced to 4.0
208 days (2.0 - 15.0) for cases that were asymptomatic without abnormal computed tomography (CT)
209 scans (n=7).

210 Two tracing studies provide informative data (Table 1; [7,8]). Infectious period was inferred
211 indirectly from data provided in Ma et al. [8], whereby infectious period was estimated as the
212 difference between the upper latent period estimate minus the serial interval. Ma et al. [8] reports
213 on 49 asymptomatic cases and inferred serial interval from infector-infectee pairs. Serial interval was
214 calculated by assuming “onset” was at first diagnosis. Hu et al. [7] reported on a case-study cluster
215 of infection within a house where the primary case was asymptomatic. Secondary infections
216 occurred 4-9 days after index case exposure, the index patient tested positive until day 29 post
217 exposure.

218 Modelling studies that have attempted to fit differing parameters depending on the severity of
219 symptoms have used differing nomenclature, for example asymptomatic, “mild” or subclinical cases
220 (Table 1).[14,15,26,27] Two papers by Davies and colleagues [14,15] model this parameter as a

221 gamma distribution with a mean periods of 5-7 days (Fig. 2); importantly, these papers assume
222 infectious period is the same for asymptomatic and symptomatic cases.

223 Pre-symptomatic, infectious period (T3)

224 Pan et al. [3] and Hoehl et al. [28] describe the cases of two individuals tracked and serially tested by
225 real-time reverse transcriptase polymerase chain reaction (RT-PCR) after being exposed to a patient
226 with confirmed infection. In the latter study, the virus was isolated from samples, indicating
227 transmission potential.

228 Four studies from China, Germany and Singapore provide informative data through tracing infections
229 from cluster of infections, and through infector-infectee pairs (Table 2).[4,9,29,30] These papers
230 included the study by Rothe et al. [9], which clarified that an asymptomatic patient visiting Germany
231 from China may have actually experienced very mild symptoms around the time of transmission
232 occurred (see discussion).

233 Five modelling papers incorporated pre-symptomatic infectious period reported as prior
234 distributions or estimated as a model output. Two papers describe the prior distribution using a
235 gamma distribution.[14,15] Tindale et al. [31] provide mean point estimates under four different
236 scenarios (two populations, early and late epidemic period). Peak et al. [32] derives estimates of the
237 pre-symptomatic infectious duration from a model of serial interval, and report scenarios where
238 there are pre-symptomatic infectious periods.

239 The approximated distributions are simulated in Figure 2, which demonstrates the between-study
240 heterogeneity in this parameter. The point estimates primarily cluster around the central tendencies
241 of the distributions, except for Tindale et al. [31], for a model reporting for late occurring cases in
242 Tianjin, China (8.2 days).

243 Post-symptom onset, infectious period (T5)

244 The T5 parameter was informed from three lines of evidence from empirically driven studies:

- 245
- 246 • time from symptoms onset to the first of two clear RT-PCR tests
 - 247 • time from symptoms to hospital discharge
 - 248 • time from symptoms to death

249 Figure 3 presents the forest plot for the mean time from symptom onset to clearance, based on
250 serial testing meta-analysis (n=15). The mean estimated duration was 13.4 days (95%CI: 10.9-15.8).
251 There was high heterogeneity across studies (Cochrane's Q; $p < 0.001$; $I^2 > 75\%$). A random effects (RE)
meta-regression model suggested significant variation depending on whether studies included

252 children as part of the sample (n=15 studies; Proportion of between-study variance explained
253 Adj. $R^2 = 43.8\%$). Overall, the model estimated studies including children had on average 5.8 days
254 shorter duration than adult only studies (95%CI: 1.7-10.0; p=0.040; SE(p)=0.003). A second univariate
255 RE meta-regression model suggested that there was non-significant increased mean duration of 4.0
256 days (95%CI: -0.6-8.6; p=0.111; SE(p)=0.005; Adj. $R^2 = 22.0\%$; n=14) for studies that included
257 moderate-severe or severe cases, relative to mild or mild-moderate severity cases.

258 High transmissibility during the first 5 days post symptom onset was described by Cheng et al. [33],
259 based on secondary attack rates for 12 infector-infectee pairs. No contacts (n=1043) with primary
260 cases were infected after five days of the index case onset of symptoms, inferred by the authors to
261 suggest transmission occurring at symptom onset (but conceivably also suggest pre-symptomatic
262 infection). Based on a cumulative density function, the authors suggest that infectiousness declines
263 rapidly from onset of infection (distribution was truncated at 30 days); estimated cumulative
264 infectiousness was 66.9% (95%CI: 28.7-94.8) by day 1, and reached 86.9% (95%CI: 64.3-99.5) by day
265 5 post-symptom onset (Figure S2).

266 For tracking studies relating to time to hospital discharge or death, raw case level data were
267 available (studies n=3).[31,34–36] Histograms of the raw data are presented in Figure 4, along with
268 the aggregated distribution. A random effect model suggested a mean duration of 18.1 days (95%ci:
269 15.1 – 21.0). However, there was significant variation across studies, with time to discharge being
270 4.96 days shorter (95%CI: 2.15- 7.76; [35]), or 3.79 days shorter (95%CI: 0.8-6.7; [31]), than time-to-
271 death [34].

272 Two modelling papers use priors (mean: 3.2-3.5 days) to represent clinical infectious period.[14,15]
273 However, the distribution for this parameter is right censored when patients are hospitalised or
274 isolated and therefore not an estimate of the full infectious period *per se*.

275 Infectious period for symptomatic cases (T3+T5)

276 Two tracing studies supplied parameter estimates for the full infectious period for patients who
277 develop symptoms. [8,29] He et al. [29] inferred from a publicly available dataset of 77 infector-
278 infectee pairs that infectiousness began 2.3 days (95% CI, 0.8–3.0 days) prior to symptom onset,
279 peaking at 0.7 days (95% CI, -0.2–2.0 days), and continued up to 7 days from onset. The authors
280 suggest that the transmission risk diminishes 7 days post symptom onset. This suggests that the
281 average infectious period, assuming a symptomatic infectious period of 7 days was approximately
282 9.3 days (7.8-10 days 95%CI, where CI is only reported for the pre-symptomatic period). He et al.
283 [29] estimated that the proportion of all transmission that was pre-symptomatic was 44% (95% CI,

284 25–69%). Ma et al. [8] analysed data from a number of countries (China, Germany, Japan, Malaysia,
285 Singapore, Vietnam), collating 1155 cases from public data. They estimate several parameters,
286 including “maximum latent period” and the serial interval. The authors estimated the infectious
287 period as maximum latent period minus the serial interval. Given their parameter estimates and
288 methodological approach, infectious period would have been 5 days (range 0-24; IQR: 2-9;
289 calculated from data presented within the paper).

290 Seven modelling papers reported duration of infectious period (T_3+T_5 ; Table 4), with the reported
291 central tendency for the distribution varying from 3-20 days. The form of the distribution offered to
292 models for this parameter varied considerably, including point estimates (deterministic models), flat
293 (uniform), Gaussian, Weibull and gamma distributions. Li et al. [27] estimated the shortest median
294 duration of 3.45 days, with a flat (uninformative) prior distribution corralled between 3-5 days. In
295 contrast, Zhu et al. [37] used a mean prior of 10 days, with the model estimated mean duration
296 being 12.5 days (variance 10; Weibull distribution). Piccolomini and Zama [38] used a fixed estimate
297 of 20 days infectious period, to model the Italian epidemic. Two papers from the same group [14,15]
298 suggested that infectious period for asymptomatic cases approximated for symptomatic cases where
299 there was no right censoring (that is, transmission being halted through isolation or hospitalisation;
300 gamma distributions of mean 5 or 7 days). Tuite et al. [26,39] also assumed the same duration for
301 “mild” and “severe” symptomatic cases (6-6.5 days).

302

303 ***Viral load dynamics***

304 Viral load was reported from 21 papers using real-time reverse transcriptase polymerase chain
305 reaction (rRT-PCR) testing, generally post-symptomatic monitoring.[3,29,40–59] Qualitatively, the
306 viral dynamics described early increase in viral load, peaking around onset or within 2-4 days of
307 symptom onset (Figure 6 for a theoretical model), before decreasing gradually over the next one to
308 three weeks post symptom onset. Maximum duration of detection ranged from approximately 20-49
309 days, with the longest duration associated with faecal samples (see below for discussion). The
310 duration where ribonucleic acid (RNA) was recoverable by RT-PCR may have been truncated due to
311 insufficient follow-up in some cases. Studies that have investigated blood samples have provided
312 some evidence for an association with severity of infection [16,60], though it is not clear whether
313 this is a consistent feature of SARS-CoV-2 infection [40].

314 It should be noted the lack of data on pre-symptomatic or asymptomatic cases with regards viral
315 load. An exception was Kam et al. [61] who describe a pre-symptomatic case in an infant. In another
316 study, Zou et al. [53] undertook serial RT-PCR testing from nasal and throat swab samples from 14
317 imported cases, and 4 secondary cases, in Guangdong, China. The dynamics of the infection in terms
318 of cycle threshold (Ct) values and RNA copy number were described; Ct values of 30.76, 27.67,
319 24.56, and 21.48 corresponding to 1.5×10^4 , 1.5×10^5 , 1.5×10^6 , and 1.5×10^7 copies per milliliter.
320 Hence, lower Ct values infer higher viral loads. The authors report on a patient without symptoms,
321 but with positive nasal swabs (Ct values, 22 to 28) and throat swabs (Ct values, 30 to 32) testing
322 positive on days 7, 10, and 11 after contact. Importantly, the authors suggest “the viral load that was
323 detected in the asymptomatic patient was similar to that in the symptomatic patients.”
324 Furthermore, Kimbell et al. [62] report that Ct values between asymptomatic (21.9 to 31.0), pre-
325 symptomatic (15.3 to 37.9), and symptomatic cases (18.6 to 29.2) within a nursing home
326 environment did not differ significantly. To et al. [59] present data on temporal profile of viral load
327 from saliva samples, and found that median initial and peak viral loads in severe cases were non-
328 significantly higher ($p > 0.5$) by approximately 1 log₁₀ higher than those in mild cases. Liu et al. [58]
329 present data showing viral load being 60 times greater for severe cases relative to mild cases.

330 This lack of pre-symptomatic data may result in left truncation of the risk distribution associated
331 with viral load and shedding. Therefore, the typical timing of peak viral shedding (whether prior to,
332 at, or after onset), and its impact on transmission, is still uncertain. He et al. [29] reported highest
333 viral load at symptom onset from patients sampled in a hospital in China. Furthermore, the author’s
334 estimate using a separate infector-infectee dataset (n=77) that 44% (95% CI: 25–69%) of infectee
335 cases were infected during the pre-symptomatic stage of the infector. Separately, a modelling paper

336 by Ferretti et al. [63] also appears to support this, estimating that 47% (0.9/2) of total transmission
337 contributing R_0 , an overall measure of transmission during an infection, was pre-symptomatic (also
338 see [33]).

339 Wölfel et al. [50] provides important data on a cohort of nine 'mild' cases which were serially tested
340 using sputum, swabs (throat and nasopharyngeal), urine and faecal samples over time. Importantly,
341 the virus was isolated, and inferences on viral replication could be made. Viral Isolation, and insights
342 into viral replication, improve inference around viral dynamics and transmission risk. The study
343 suggested high viral loads shortly after symptom onset, which declined thereafter over time. Positive
344 cultures were found from day 3-8 post-symptom onset (Figure 5), and the minimum 5% isolation
345 success was achieved up to 9.8 (95% CI: 8.5-21.8) days post onset from throat and lung samples but
346 not faeces, blood or urine.

347 Discussion

348 Inferring infectiousness was challenging given the heterogeneity of evidence available. Virological
349 diagnostic studies provide robust time series of infection, however, is limited by inferring the
350 relationship between PCR diagnostics and infectiousness. These data can also be affected by
351 sampling procedure and sample sites (e.g. upper respiratory, lower respiratory, faeces, urine, blood).
352 We have excluded RT-PCR durations based on faecal sampling due to the uncertainty whether these
353 data pertain to transmission potential ([50]; see below). Virological studies where culturing has
354 taken place, and where viral replication can be inferred would also be considered superior data to
355 infer infectious period, relative to estimates of viral load alone.[50] Where this has taken place, the
356 data would suggest average infectious periods of up to 9.8 days post-symptoms. Recent modelling
357 work suggest that the duration of viral detectability could overestimate the infectious period
358 somewhere between 2-6 days.[64]

359 Viral load studies suggest peak viral load occurs close to symptom onset (potentially, -1 to 7 days of
360 onset), however there is uncertainty whether this typically occurs prior to, on, or after onset (Figure
361 6 for conceptual model). High viral loads, measured as Ct values, have been recorded for one week
362 to 20 days post symptom onset, with a general decreasing trend with time. For example, To et al.
363 [59] estimates a declining slope per day for log₁₀ RNA copies per ml of -0.15 (95% CI -0.19 to -0.11;
364 $R^2=0.71$). There are some studies reporting associations between viral load and symptom severity,
365 with higher metrics of viral load in severe cases.[3,58,59] However, Zou et al. [53], and more recent
366 data from Italy,[64,65] suggest similar viral loads in symptomatic and asymptomatic cases.

367 We tested the hypothesis that severity of symptoms had an effect on symptomatic infectious
368 duration using a meta-regression approach. There was a trend towards studies that included severe
369 cases tended to have longer duration (estimated to be 4.0 days longer), but the effect was not
370 significant. Some studies have reported an association between duration of infectiousness and
371 severity (e.g. [58]). But uncertainty of whether this is robust remains.

372 Virological studies that included children (either mixed adult children, or children only cohorts)
373 appeared to have shorter T5 durations (estimate: 5.8 days shorter). Liao et al. [66] present data
374 which suggests that children and 'young adults' (<35 years old) infected cases exhibited long
375 incubation time (exposure to symptom on-set; mean 7.2 days), and short serial interval (mean 6.5
376 days; median 1.9 days; time from onset in primary to onset in secondary case).

377 Contact tracing studies provided robust evidence of transmission events, and therefore
378 infectiousness, but can be limited by the inferred timing of events, and symptoms experienced, due

379 to the self-reported nature of data collection (recall bias). The subjective nature of self-reporting
380 indeed can have an impact on case definitions of ‘asymptomatic’, which has led to some doubt on
381 asymptomatic transmission in one case.[9] Rothe et al. [9] describe a case of apparent asymptomatic
382 transmission from a Chinese visitor to business associates in Germany, which was cast into doubt
383 when health officials reported that the patient had indeed experienced some, albeit minor,
384 symptoms.[67] Rothe et al. [9] subsequently updated the clarification of the patients self-reported
385 symptoms during the presumed asymptomatic infectious period, which included “feeling warm” and
386 “feeling cold”. However, the patient only “recognized getting sick” after she returned to China on
387 day four after the presumed exposure event.

388 Modelling parameters provide information on how COVID-19 data are being used and interpreted in
389 the research community, given the limited data available. Posterior estimates also provide
390 information on the parameter space at which infectious period central tendency reside, given other
391 parameters and assumptions in the model. Models used highly varied approaches to modelling
392 infectious period, which in turn resulted in highly variable parameter estimates used to inform the
393 studies.

394 *Overall duration findings*

395 There are few data for the precise definition of the asymptomatic infectious period (T2) parameter.
396 Some reported asymptomatic cases can actually be pre-symptomatic, when cases are subject to
397 follow-up (e.g.[66]; see discussion above). However, Hu et al. [7] do provide the data for
398 asymptomatic cases [that remain asymptomatic] across their presumed infectious period. Therefore,
399 in the first instance a parameter mimicking their data is probably the best available data. Note, there
400 is a large variation in this data parameter, and a gamma distribution of a shape alpha 3, beta 2, mean
401 6, may be appropriate for the initial model runs. Despite these being the primary informative data,
402 caution is required, given the uncertainty around the relationship between RT-PCR results and
403 infectiousness. Overall, an informed central tendency of ~6 days, with very low probability draws for
404 durations >20 days for the T2 parameter may be considered given the current state of knowledge.

405 The pre-symptomatic period is sometimes referred to as ‘preclinical infectious’ period (parameter
406 T3). This has been estimated from several papers, and the central tendency of these estimates vary
407 from <1 - 4 days, cautiously approximating to 2 days, on average. The maximal reported period for
408 T3 from any population, was reported by Tindale et al. [31] at 8.2 days. Current models have used
409 central tendency estimates of 0.5 to 2.4 days.[14,15,26,39] It should be noted, that this period could
410 also be measured as the difference between incubation and latent period, or the difference between
411 serial interval and incubation period.[12] The relative consistency around the duration of this period

412 allows for some confidence of its distribution. Current understanding of viral dynamics of infection
413 suggest that viral load and shedding increases during post-latent phase, peaking around onset [for
414 symptomatic cases], before declining.[29,50,53] This aspect of the natural history of infection may
415 be important when attempting to model transmission dynamics.

416 Length of infectious period in symptomatic cases that do not isolate (T5 parameter) has also been
417 rarely directly measured in the literature, as serial monitoring of patients in terms of symptoms or
418 viral load (rt-PCR) generally occurs after diagnosis and/or after admission to hospital [from a
419 modelling perspective, this means cases are censored as they are assumed to no longer contribute
420 to transmission]. If natural progression of infection after diagnosis or hospital admission mimics the
421 course of infection for those who do not isolate, the review of the literature describing time to two
422 clear tests is informative. Symptom onset to serial testing clearance [assessed the time to first of two
423 RT-PCR clear tests] averaged 13.4 days (95%CI: 10.9-15.8) from our meta-analysis. In the maximal
424 case, where patients succumb or fully recover from infection, time from symptoms to death or
425 discharge may be informative. Studies that collated such information suggest mean durations of
426 18.07 days (95%ci: 15.14 - 20.99), but with time to discharge being 4.96 days shorter (95%CI: 2.15-
427 7.76) on average than time to death. These values may represent an over estimation of the
428 infectious period; one study suggested that there was on average 2.5 days between end of
429 infectiousness and 'removal' (recovery or death).[37]

430 Cheng et al. [33] provided evidence of transmissibility, based on attack rate from primary to
431 secondary cases, at around symptom onset. The authors estimate cumulative infectiousness from
432 onset, which suggests that 67% of total infectiousness potential occurs by the first day post-onset.
433 Most of the total infectiousness occurs within 5 days (86.9%) post onset, with the remaining
434 infectiousness potential (13.1%) being distributed up to day 30 (this truncation is an assumption by
435 the authors). It is possible that pre-symptomatic transmission occurred during this study, but the
436 authors do not estimate what proportion of transmissions occurred during a pre-symptomatic
437 infectious period, or its potential duration.

438 A model by He et al. [29] is informative for overall symptomatic duration (T3+T5), using 77 infector-
439 infectee pairs where COVID-19 transmission occurred in China. The study reported that
440 infectiousness was apparent on average 2.5 days prior to symptoms, reached a peak in risk at 0.6
441 days before symptoms, and decline up until 7 days after onset (9.5 days total infectious period). The
442 proportion of transmission before symptom onset (area under the curve) was estimated as 44%
443 (95% CI, 25–69%), based on inferences on incubation period. The authors suggest their data
444 supported the view that transmission risk decline substantially after 7 days post-symptoms onset.

445 Model estimates used for infectious period parameter appears to be shorter than virological studies
446 tracking RNA viral load over time. For example, Liu et al.[27] fitted a flat prior distribution for mean
447 duration (D) fixed to vary between: $2 \leq D \leq 5$ days, and Lavezzo et al. [64] fixed infectious period to 2
448 days in their epidemic model; whereas viral repeat testing studies provide evidence to suggest high
449 viral loads can be detected to up 20 days [e.g. pharyngeal swabs], and potentially longer from faecal
450 samples (up to 3-4 weeks post symptoms onset). Oral-faecal transmission risk is currently unknown,
451 but some doubt has been raised about studies that have reported positive RTPCR test results (see
452 [68]; but there may be some evidence of the risk amongst children; [69]). Wölfel et al. [50] has
453 produced an important study that provides some data on viral replication, and the site and duration
454 over which this may be taking place. Their data suggests that viral replication, with high viral loads,
455 occur in the upper respiratory tract, over the first week of symptoms peaking in day 4. Virus could
456 not be isolated from faecal samples, despite high RNA concentration. Furthermore, virus was not
457 isolated from blood or urine in that study.[50]

458 **Study limitations**

459 Overall, the studies included were of good quality, though due to the rapid need for information
460 from the global research community many papers are pre-prints that have yet to be reviewed (at
461 time of writing). Many papers were limited in terms of sample sizes, with several papers being case
462 studies of one patient or single cluster outbreaks. There was a diversity of methods employed to
463 infer dynamics of infectiousness across studies, and therefore the evidential base was variable. Some
464 issues around nomenclature were noted, including definitions of asymptomatic, infectious period,
465 latent, and incubation period. It is possible the same data may have been used across different
466 studies, especially where publicly available data were used.

467 There was significant heterogeneity across study findings, and this was related to diversity of clinical
468 findings and methods employed. The meta-analysis employed for one parameter (T_5) using
469 virological studies, where cross study comparisons could be made, suggested that the heterogeneity
470 was high. Fu et al.[70] cautions against combining studies to give an overall estimate without
471 exploring subgroup or meta-regression analysis, which we have done here. The meta-regression was
472 based on a small number of studies ($n=12-13$). Cochrane's handbook suggests 10 studies for each
473 level of a meta-regression, however in practice much lower numbers have been used to test
474 hypotheses [22], as is the case here. Fu et al. [70] recommend a minimum of 4 studies per category,
475 and therefore we dichotomised our predictor variables to ensure we met this minimum. Aggregating
476 our categories resulted in crude findings.

477 Another limitation is that a systematic review was not undertaken to inform this research, hence
478 there is a possibility that some relevant studies were overlooked. However, comprehensive search
479 strategies were conducted by two independent research groups to inform this research, hence
480 limiting the potential for missing key studies.

481 **Conclusion**

482 There are few data to inform asymptomatic infectious period (T2 parameter). One study provide
483 data that suggest a median period of 4-9.5 days, however, given the viral dynamics, this distribution
484 could have an extended tail with low probability long infectious periods of up to 20 days. The pre-
485 symptomatic infectious phase (T3) is quite narrowly defined to a mean of approximately 2 days
486 (range: <1-4) within the literature. However, there is great uncertainty around the infectious period
487 from onset to recovery or death (T5 parameter). The symptom onset until clearance (based on two
488 negative RT-PCR tests) parameter estimate of 13.4 days (95%CI: 10.9-15.8) is informative for T5
489 parameter, only if one assumes that RT-PCR positive results equate to having infectious potential.
490 Many current models corral the infectious period to shorter time periods than what virological
491 studies have suggested, with one recent study suggesting that duration of viral detectability over-
492 estimates the infectious period on average by 2-6 days. While viral RNA can be detected for long
493 periods of time, especially from faecal samples, the ability to isolate the virus ifrom nfecteds cases
494 quickly declines after one-week post-symptoms. Some modelling papers have assumed that
495 infectious period is invariant to whether cases are asymptomatic or symptomatic, however, the data
496 available are not yet rich enough to inform whether this is a good assumption. Similarly, it is not yet
497 established whether viral loads are similar between asymptomatic and mild, moderate, or severe
498 symptomatic cases, with conflicting reports in the literature.

499 **Funding:** All investigators are full-time employees (or retired former employees) of University
500 College Dublin, the Irish Department of Food and the Marine (DAFM), or the Irish Health Information
501 and Quality Authority (HIQA). No additional funding was obtained for this research.

502 **Author contributions:** AWB conducted the eligibility screening of shortlisted studies, extracted the
503 data and conducted the analyses with input from all authors; AC, KH and FB conducted the initial
504 literature searches; DM, KOB, KW conducted searches and screened shortlisted studies; AWB
505 completed the initial draft of the manuscript; CM reviewed the statistical methods; CM and MC
506 undertook quality control interim review; All authors read and approved the final manuscript.

507 **Data statement:** The data and code are presented in supplementary material

508 **Competing interests:** All authors have completed the ICMJE uniform disclosure form at
509 www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the submitted
510 work; no financial relationships with any organisations that might have an interest in the submitted
511 work in the previous three years; no other relationships or activities that could appear to have
512 influenced the submitted work

513 **Patient and public involvement statement:** It was not appropriate or possible to involve patients or
514 the public in the design, or conduct, or reporting, or dissemination plans of our research

515

516 **References**

- 517 1 Wu F, Zhao S, Yu B, *et al.* A new coronavirus associated with human respiratory disease in
518 China. *Nature* 2020;**579**:265–9.
- 519 2 Li Q, Guan X, Wu P, *et al.* Early Transmission Dynamics in Wuhan, China, of Novel
520 Coronavirus–Infected Pneumonia. *The New England Journal of Medicine* 2020;**382**:1199–
521 207.
- 522 3 Pan Y, Zhang D, Yang P, *et al.* Viral load of SARS-CoV-2 in clinical samples. *The Lancet*
523 *Infectious Diseases* 2020;**20**:411–2.
- 524 4 Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel
525 coronavirus in Wuhan, China. *The Lancet* 2020;**395**:497–506.
- 526 5 Russell TW, Hellewell J, Jarvis CI, *et al.* Estimating the infection and case fatality ratio for
527 coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the
528 Diamond Princess cruise ship, February 2020. *Eurosurveillance* 2020;**25**:2000256.
- 529 6 Onder G, Rezza G, Brusaferro S. Case-fatality rate and characteristics of patients dying in
530 relation to COVID-19 in Italy. *Jama* 2020.
- 531 7 Hu Z, Song C, Xu C, *et al.* Clinical characteristics of 24 asymptomatic infections with
532 COVID-19 screened among close contacts in Nanjing, China. *Science China Life Sciences*
533 2020;:1–6.
- 534 8 Ma S, Zhang J, Zeng M, *et al.* Epidemiological parameters of coronavirus disease 2019: a
535 pooled analysis of publicly reported individual data of 1155 cases from seven countries.
536 *medRxiv* 2020.
- 537 9 Rothe C, Schunk M, Sothmann P, *et al.* Transmission of 2019-nCoV infection from an
538 asymptomatic contact in Germany. *New England Journal of Medicine* 2020;**382**:970–1.
- 539 10 Bai Y, Yao L, Wei T, *et al.* Presumed asymptomatic carrier transmission of COVID-19.
540 *Jama* 2020.
- 541 11 Anderson RM, Heesterbeek H, Klinkenberg D, *et al.* How will country-based
542 mitigation measures influence the course of the COVID-19 epidemic? *The Lancet*
543 2020;**395**:931–4.
- 544 12 Casey M, Collins A, Hunt K, *et al.* Pre-symptomatic transmission of SARS-CoV-2
545 Infection. 2020.
- 546 13 McEvoy D, Collins A, Byrne AW, *et al.* The relative infectiousness of asymptomatic
547 versus symptomatic infected persons with COVID-19 – A review of data available until 8
548 th April 2020. 2020.
- 549 14 Davies NG, Klepac P, Liu Y, *et al.* Age-dependent effects in the transmission and
550 control of COVID-19 epidemics. *medRxiv* 2020.

- 551 15 Davies NG, Kucharski AJ, Eggo RM, *et al.* The effect of non-pharmaceutical
552 interventions on COVID-19 cases, deaths and demand for hospital services in the UK: a
553 modelling study. *medRxiv* 2020.
- 554 16 HIQA. Evidence summary for COVID-19 viral load over course of infection. Health
555 Information and Quality Authority, Ireland. Access date: 1st April 2020.
556 [https://www.hiqa.ie/reports-and-publications/health-technology-assessment/evidence-](https://www.hiqa.ie/reports-and-publications/health-technology-assessment/evidence-summary-covid-19-viral-load-over)
557 [summary-covid-19-viral-load-over](https://www.hiqa.ie/reports-and-publications/health-technology-assessment/evidence-summary-covid-19-viral-load-over) (accessed 1 Apr 2020).
- 558 17 HIQA. Evidence summary for asymptomatic transmission of COVID-19. Health
559 Information and Quality Authority, Ireland. Access date: 1st April 2020.
560 [https://www.hiqa.ie/reports-and-publications/health-technology-assessment/evidence-](https://www.hiqa.ie/reports-and-publications/health-technology-assessment/evidence-summary-asymptomatic-transmission)
561 [summary-asymptomatic-transmission](https://www.hiqa.ie/reports-and-publications/health-technology-assessment/evidence-summary-asymptomatic-transmission)
- 562 18 HIQA. Protocol for evidence synthesis support - COVID-19. Health Information and
563 Quality Authority, Ireland. Access date: 1st April 2020.
564 [https://www.hiqa.ie/sites/default/files/2020-04/Protocol-for-HIQA-COVID-19-evidence-](https://www.hiqa.ie/sites/default/files/2020-04/Protocol-for-HIQA-COVID-19-evidence-synthesis-support_1-2.pdf.pdf)
565 [synthesis-support_1-2.pdf.pdf](https://www.hiqa.ie/sites/default/files/2020-04/Protocol-for-HIQA-COVID-19-evidence-synthesis-support_1-2.pdf.pdf)
- 566 19 Munn Z, Peters MD, Stern C, *et al.* Systematic review or scoping review? Guidance
567 for authors when choosing between a systematic or scoping review approach. *BMC*
568 *medical research methodology* 2018;**18**:143.
- 569 20 Tricco AC, Langlois EV, Straus SE. *Rapid reviews to strengthen health policy and*
570 *systems: a practical guide*. World Health Organization Geneva 2017.
- 571 21 Wan X, Wang W, Liu J, *et al.* Estimating the sample mean and standard deviation
572 from the sample size, median, range and/or interquartile range. *BMC medical research*
573 *methodology* 2014;**14**:135.
- 574 22 Higgins JPT, Wells GA. Cochrane handbook for systematic reviews of interventions.
575 2011.
- 576 23 Brockwell SE, Gordon IR. A comparison of statistical methods for meta-analysis.
577 *Statistics in medicine* 2001;**20**:825–40.
- 578 24 Higgins JP, Thompson SG, Deeks JJ, *et al.* Measuring inconsistency in meta-analyses.
579 *BMJ: British Medical Journal* 2003;**327**:557.
- 580 25 Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-
581 regression. *Statistics in medicine* 2004;**23**:1663–82.
- 582 26 Tuite AR, Fisman DN, Greer AL. Mathematical modelling of COVID-19 transmission
583 and mitigation strategies in the population of Ontario, Canada. *CMAJ: Canadian Medical*
584 *Association Journal= Journal de L'association Medicale Canadienne* 2020.
- 585 27 Li R, Pei S, Chen B, *et al.* Substantial undocumented infection facilitates the rapid
586 dissemination of novel coronavirus (SARS-CoV2). *Science* 2020.

- 587 28 Hoehl S, Rabenau H, Berger A, *et al.* Evidence of SARS-CoV-2 infection in returning
588 travelers from Wuhan, China. *New England Journal of Medicine* 2020;**382**:1278–80.
- 589 29 He X, Lau EH, Wu P, *et al.* Temporal dynamics in viral shedding and transmissibility of
590 COVID-19. *Nature Medicine* 2020;:1–4.
- 591 30 Wei WE, Li Z, Chiew CJ, *et al.* Presymptomatic Transmission of SARS-CoV-2—
592 Singapore, January 23–March 16, 2020. *Morbidity and Mortality Weekly Report*
593 2020;**69**:411.
- 594 31 Tindale L, Wallinga J, Coombe M, *et al.* Transmission interval estimates suggest pre-
595 symptomatic spread of COVID-19. [https://www.medrxiv.org/content/101101/202003](https://www.medrxiv.org/content/101101/2020030320029983v1)
596 [0320029983 v1](https://www.medrxiv.org/content/101101/2020030320029983v1) 2020.
- 597 32 Peak CM, Kahn R, Grad YH, *et al.* Modeling the Comparative Impact of Individual
598 Quarantine vs. Active Monitoring of Contacts for the Mitigation of COVID-19. *medRxiv*
599 2020.
- 600 33 Cheng H-Y, Jian S-W, Liu D-P, *et al.* High transmissibility of COVID-19 near symptom
601 onset. *medRxiv* 2020.
- 602 34 Linton NM, Kobayashi T, Yang Y, *et al.* Incubation period and other epidemiological
603 characteristics of 2019 novel coronavirus infections with right truncation: a statistical
604 analysis of publicly available case data. *Journal of clinical medicine* 2020;**9**:538.
- 605 35 Kramer M, Pigott D, Xu B, *et al.* *Epidemiological data from the nCoV-2019 Outbreak:*
606 *Early Descriptions from Publicly Available Data.* 2020.
- 607 36 Xu B, Gutierrez B, Mearu S, *et al.* Epidemiological data from the COVID-19 outbreak,
608 real-time case information. *Scientific data* 2020;**7**:1–6.
- 609 37 Zhu H. Transmission Dynamics and Control Methodology of COVID-19: a Modeling
610 Study. *medRxiv* 2020;:2020.03.29.20047118. doi:10.1101/2020.03.29.20047118
- 611 38 Piccolomiini EL, Zama F. Monitoring Italian COVID-19 spread by an adaptive SEIRD
612 model. *medRxiv* 2020.
- 613 39 Tuite AR, Greer AL, Fisman DN. COVID-2019 Transmission Model 10-March-2020.
614 University of Toronto
- 615 40 Holshue ML, DeBolt C, Lindquist S, *et al.* First case of 2019 novel coronavirus in the
616 United States. *New England Journal of Medicine* 2020;**382**.
- 617 41 Kam K, Yung CF, Cui L, *et al.* A Well Infant with Coronavirus Disease 2019 with High
618 Viral Load. *Clinical Infectious Diseases* 2020.
- 619 42 Kim JY, Ko J-H, Kim Y, *et al.* Viral load kinetics of SARS-CoV-2 infection in first two
620 patients in Korea. *Journal of Korean medical science* 2019;**35**.

- 621 43 Kujawski SA, Wong KK, Collins JP, *et al.* First 12 patients with coronavirus disease
622 2019 (COVID-19) in the United States. *medRxiv* 2020.
- 623 44 Lim J, Jeon S, Shin H-Y, *et al.* Case of the index patient who caused tertiary
624 transmission of Coronavirus disease 2019 in Korea: the application of lopinavir/ritonavir
625 for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. *Journal of*
626 *Korean Medical Science* 2020;**35**.
- 627 45 Marchand-Sénécal X, Kozak R, Mubareka S, *et al.* Diagnosis and Management of First
628 Case of COVID-19 in Canada: Lessons applied from SARS. *Clinical Infectious Diseases* 2020.
- 629 46 Tan LV, Ngoc NM, That BTT, *et al.* Duration of viral detection in throat and rectum of
630 a patient with COVID-19. 2020.
- 631 47 Thevarajan I, Nguyen TH, Koutsakos M, *et al.* Breadth of concomitant immune
632 responses prior to patient recovery: a case report of non-severe COVID-19. *Nature*
633 *Medicine* 2020;**26**:453–5.
- 634 48 To KK, Tsang OT, Chik-Yan YC, *et al.* Consistent detection of 2019 novel coronavirus
635 in saliva. *Clinical infectious diseases: an official publication of the Infectious Diseases*
636 *Society of America* 2020.
- 637 49 Woelfel R, Corman VM, Guggemos W, *et al.* Clinical presentation and virological
638 assessment of hospitalized cases of coronavirus disease 2019 in a travel-associated
639 transmission cluster. *medRxiv* 2020.
- 640 50 Wölfel R, Corman VM, Guggemos W, *et al.* Virological assessment of hospitalized
641 patients with COVID-2019. *Nature* 2020;:1–10.
- 642 51 Xu T, Chen C, Zhu Z, *et al.* Clinical features and dynamics of viral load in imported and
643 non-imported patients with COVID-19. *International Journal of Infectious Diseases: IJID:*
644 *Official Publication of the International Society for Infectious Diseases* 2020.
- 645 52 Young BE, Ong SWX, Kalimuddin S, *et al.* Epidemiologic Features and Clinical Course
646 of Patients Infected with SARS-CoV-2 in Singapore. *JAMA-Journal of the American Medical*
647 *Association* 2020.
- 648 53 Zou L, Ruan F, Huang M, *et al.* SARS-CoV-2 viral load in upper respiratory specimens
649 of infected patients. *New England Journal of Medicine* 2020;**382**:1177–9.
- 650 54 Cao B, Wang Y, Wen D, *et al.* A trial of lopinavir–ritonavir in adults hospitalized with
651 severe Covid-19. *New England Journal of Medicine* 2020.
- 652 55 Chen W, Lan Y, Yuan X, *et al.* Detectable 2019-nCoV viral RNA in blood is a strong
653 indicator for the further clinical severity. *Emerging Microbes & Infections* 2020;**9**:469–73.
- 654 56 Goh KJ, Choong MC, Cheong EH, *et al.* Rapid Progression to Acute Respiratory
655 Distress Syndrome: Review of Current Understanding of Critical Illness from COVID-19
656 Infection. *Ann Acad Med Singapore* 2020;**49**:1–9.

- 657 57 Hill KJ, Russell CD, Clifford S, *et al.* The index case of SARS-CoV-2 in Scotland: a case
658 report. *The Journal of Infection*
- 659 58 Liu Y, Yan L-M, Wan L, *et al.* Viral dynamics in mild and severe cases of COVID-19. *The*
660 *Lancet Infectious Diseases*
- 661 59 To KK-W, Tsang OT-Y, Leung W-S, *et al.* Temporal profiles of viral load in posterior
662 oropharyngeal saliva samples and serum antibody responses during infection by SARS-
663 CoV-2: an observational cohort study. *The Lancet Infectious Diseases* 2020.
- 664 60 Fang Z, Zhang Y, Hang C, *et al.* Comparisons of nucleic acid conversion time of SARS-
665 CoV-2 of different samples in ICU and non-ICU patients. *The Journal of Infection* 2020.
- 666 61 Kam KQ, Yung CF, Cui L, *et al.* A Well Infant with Coronavirus Disease 2019 (COVID-
667 19) with High Viral Load. *Clinical Infectious Diseases: An Official Publication of the*
668 *Infectious Diseases Society of America* 2020.
- 669 62 Kimball A, Hatfield KM, Arons M, *et al.* Asymptomatic and Presymptomatic SARS-
670 CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility-King County,
671 Washington, March 2020. *MMWR Morbidity and mortality weekly report* 2020;**69**.
- 672 63 Ferretti L, Wymant C, Kendall M, *et al.* Quantifying SARS-CoV-2 transmission suggests
673 epidemic control with digital contact tracing. *Science* 2020.
- 674 64 Lavezzo E, Franchin E, Ciavarella C, *et al.* Suppression of COVID-19 outbreak in the
675 municipality of Vo, Italy. *medRxiv* 2020.
- 676 65 Cereda D, Tirani M, Rovida F, *et al.* The early phase of the COVID-19 outbreak in
677 Lombardy. *Italy [published online ahead of print March 20, 2020] arXiv* 2020.
- 678 66 Liao J, Fan S, Chen J, *et al.* Epidemiological and clinical characteristics of COVID-19 in
679 adolescents and young adults. *medRxiv* 2020.
- 680 67 Kupferschmidt K. Study claiming new coronavirus can be transmitted by people
681 without symptoms was flawed. *Science* 2020;**3**.
- 682 68 Hu F, Chen F, Wang Y, *et al.* Failed detection of the full-length genome of SARS-CoV-2
683 by ultra-deep sequencing from the recovered and discharged patients retested viral PCR
684 positive. *medRxiv* 2020.
- 685 69 Xing Y, Ni W, Wu Q, *et al.* Prolonged presence of SARS-CoV-2 in feces of pediatric
686 patients during the convalescent phase. *medRxiv* 2020.
- 687 70 Fu R, Gartlehner G, Grant M, *et al.* Conducting quantitative synthesis when
688 comparing medical interventions: AHRQ and the Effective Health Care Program. *Journal*
689 *of clinical epidemiology* 2011;**64**:1187–97.
- 690 71 Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult
691 inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*
692 2020.


- 693 72 Ferguson N, Laydon D, Nedjati Gilani G, *et al.* Report 9: Impact of non-
694 pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare
695 demand. 2020.
- 696 73 Cai J, Xu J, Lin D, *et al.* A Case Series of children with 2019 novel coronavirus
697 infection: clinical and epidemiological features. *Clinical Infectious Diseases* 2020.
- 698 74 Cai Q, Huang D, Ou P, *et al.* COVID-19 in a Designated Infectious Diseases Hospital
699 Outside Hubei Province, China. *Allergy* 2020.
- 700 75 Chen D, Xu W, Lei Z, *et al.* Recurrence of positive SARS-CoV-2 RNA in COVID-19: A
701 case report. *International Journal of Infectious Diseases* 2020.
- 702 76 Cheng S-C, Chang Y-C, Chiang Y-LF, *et al.* First case of Coronavirus Disease 2019
703 (COVID-19) pneumonia in Taiwan. *Journal of the Formosan Medical Association* 2020.
- 704 77 Lee N-Y, Li C-W, Tsai H-P, *et al.* A case of COVID-19 and pneumonia returning from
705 Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic. *Journal of*
706 *Microbiology, Immunology and Infection* 2020.
- 707 78 Ling Y, Xu S-B, Lin Y-X, *et al.* Persistence and clearance of viral RNA in 2019 novel
708 coronavirus disease rehabilitation patients. *Chinese medical journal* 2020.
- 709 79 Liu F, Xu A, Zhang Y, *et al.* Patients of COVID-19 may benefit from sustained
710 lopinavir-combined regimen and the increase of eosinophil may predict the outcome of
711 COVID-19 progression. *International Journal of Infectious Diseases* 2020.
- 712 80 Qu YM, Kang EM, Cong HY. Positive result of Sars-Cov-2 in sputum from a cured
713 patient with COVID-19. *Travel Medicine and Infectious Disease* 2020;:101619–101619.
- 714 81 Yuan J, Kou S, Liang Y, *et al.* Clinical Characteristics on 25 Discharged Patients with
715 COVID-19 Virus Returning. *medRxiv* 2020;:2020.03.06.20031377.
716 doi:10.1101/2020.03.06.20031377
- 717 82 Chen J, Qi T, Liu L, *et al.* Clinical progression of patients with COVID-19 in Shanghai,
718 China. *Journal of Infection* 2020.
- 719 83 Le HT, Nguyen LV, Tran DM, *et al.* The first infant case of COVID-19 acquired from a
720 secondary transmission in Vietnam. *The Lancet Child & Adolescent Health* 2020.
- 721 84 Qiu H, Wu J, Hong L, *et al.* Clinical and epidemiological features of 36 children with
722 coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study.
723 *The Lancet Infectious Diseases* 2020.
- 724 85 Wu Y, Guo C, Tang L, *et al.* Prolonged presence of SARS-CoV-2 viral RNA in faecal
725 samples. *The Lancet Gastroenterology & Hepatology* 2020;5:434–5.
- 726 86 Lourenço J, Paton R, Ghafari M, *et al.* Fundamental principles of epidemic spread
727 highlight the immediate need for large-scale serological surveys to assess the stage of the
728 SARS-CoV-2 epidemic. *medRxiv* 2020.

729

730

731 **Tables and figures**


732



733

734 **Figure 1:** Simulation of the parameter distribution inferred for duration infectious period for
735 asymptomatic cases (T2) inferred infectious period for Davies et al. (2020a), grey/blue curve, Davies
736 et al. (2020b) pink curve [model priors]. Green curve: Ma et al. (2020). Histogram is the distribution
737 of asymptomatic cases to two clear tests reported by Hu et al. (2020). Reference lines are point
738 estimates reported from Zhou et al. (2020), Li et al. (2020), and Tuite et al. (2020a &
739 b).[7,8,14,15,26,27,39,71]

740




741

742 **Figure 2:** Simulation of the parameter distribution used for T3 (the duration of the pre-symptomatic
743 infectious period for those infected individuals who subsequently develop symptoms). Curves
744 represent simulated approximations of distributions, given information provided from primary
745 literature. Vertical lines represent point estimates where distributions could not be inferred (see
746 table 2). 1. Peak et al. [posterior]; 2. Davies et al. 2020b [prior]; 3. Rothe et al. 2020; 4. He et al.
747 2020; 5. Davies et al. 2020a [prior]; 6. Wei et al. 2020. [9,14,15,29,30,32]

748


749



750

751 **Figure 3:** Forest plot comparison of the mean duration from onset of symptoms to death or recovery
752 (T5) based on virological studies

753



754

755 **Figure 4:** Frequency distribution of **T5**, time from onset of symptoms to recovery (here hospital
756 discharge or death), using patient level raw data from Kraemer et al. ([35,36]; pink bars), Linton et al.
757 ([34]; purple bars) and Tindale et al. ([31]; green bars). Blue solid line is the kernel density of the
758 aggregated dataset Dashed lines represent the mean and 95%CI from a random effects regression
759 model.

760

Positive culture



Negative culture




0 2 4 6 8 10 12 14
Days after symptom onset

761

762 **Figure 5:** Timeline for positive culture results of SARS-COV2 from throat, sputum and stool samples;
763 Yellow line = Throat swabs; Orange line = Sputum samples; Blue line = Stool samples; Adapted from
764 Wölfel et al.[50].

765

766



767

768 **Figure 6:** Composite inferred model for cycle threshold (CT) value changes from serial RT-PCR testing
769 for SARS-COV2; currently uncertain whether peak viral load typically occurs prior to, on, or post-
770 symptom onset (primary literature informing this model includes [29,50,53,59]).

771

772 **Table 1:** Reported infectious period (IP) for asymptomatic cases (T5 parameter) from virological
 773 studies where serial diagnostic tests were undertaken to infer IP; tracking studies where IP is
 774 inferred from contact tracing; modelling studies where IP is reported as a prior (assumed parameter
 775 value) or an posterior estimate.

No.	Study	Countries	Parameter (days)	n	Central tendency reported	Variation (days; inclus.)	Comment
<i>Virological studies</i>							
[71]	Zhou et al. (2020)	China	11 days	1	Max		This study serially swabbed and tested symptomatic (17) and asymptomatic (1) cases via RTPCR. The single asymptomatic case tested positive up to 11 days post contact with an infected patient (presumed point of exposure).
[7]	Hu et al. (2020)	China	9.5 days	24	Median	1-21 range	Serial testing. Period between “onset” (where onset relates to first positive test) and clearance, adjudged via two negative RTPCR tests, deemed by the authors to be the ‘communicable period’. IQR: 3.5-13
<i>Tracking studies</i>							
[8]	Ma et al. (2020)	China, Germany, Japan, Singapore, South Korea, Malaysia, Vietnam	7.25 days*	49	Mean	5.91-8.69 (95%CI)	*Ma et al. (2020) does not report infectious period for asymptomatic cases explicitly within their paper. The authors estimated the infectious period as the upper estimated latent period minus the serial interval, using a dataset of 1155 cases from several countries (latent period was estimated with 11 infector-infectee pairs; serial interval was estimated from 689 infector-infectee pairs). Ma et al. (2020) reported a mean upper limit of latent period of 2.52 days; the mean serial interval for asymptomatic cases (using date of diagnosis for onset) was estimated to be 9.77 (94%CI: 8.43, 11.21).
[7]	Hu et al.	China		3		4-9	Cluster of infection within a

	(2020)					range	family, where the primary case was asymptomatic. The transmissions to secondary cases occurred over a period 4-9 days post the presumed point of exposure for the primary case.
Modelling studies							
[27]	Li et al. (2020)	China	3.5* [posterior from a model estimating duration for undocumented cases]		Median	3.19-3.78 95%CI	Li et al. (2020) do not explicitly attempt to model asymptomatic cases, or their infectious duration. Instead the population infected is divided into 'documented' and 'undocumented'. Documented were all cases where patients had symptoms severe enough to be confirmed infected; all other cases were considered undocumented. Therefore, this estimate represents asymptomatic and 'mild' cases. The 95%CI around the median infectious period estimate was 3.19-3.78
[26,39]	Tuite et al. (2020a &b)	Canada	6-6.5 [Prior]		[Fixed parameter within a deterministic model]		Mathematical model [deterministic], with a fixed parameter estimate of 6 or 6.5 days. Important to note that duration for 'mild' was equal to severe cases.
[14]	Davies et al. (2020) (a)	UK	7 days [Prior]		Mean		Model with asymptomatic infection compartment. Modelled with a gamma distribution, beta 1.4; alpha 5. Despite, the subclinical aspect of this parameter, it could be considered analogous to total infectious period without intervention.
[15]	Davies et al. (2020) (b)	UK	5 days [Prior]		Mean		Model with asymptomatic infection compartment. Modelled with a gamma distribution, k=4. Authors: "Assumed to be the same duration as total infectious period for clinical cases, including preclinical transmission"

777 **Table 2:** Reported infectious period (IP) for pre-symptomatic cases (T3 parameter) from virological
 778 studies where serial diagnostic tests were undertaken to infer IP; tracking studies where IP is
 779 inferred from contact tracing; modelling studies where IP is reported as a prior (assumed parameter
 780 value) or an posterior estimate.

	Study	Location	Parameter (days)	Central tendency reported	Variation (days; inclus.)	Comment
	<i>Virological studies</i>					
[3]	Pan et al. (2020)	Beijing, China	1	Median		Case study of two individuals tracked due to exposure to an infected patient was serially tested prior to onset of symptoms.
[28]	Hoehl et al. (2020)	Flight from Wuhan to Germany	1	Median		Case study of serially tested at risk cohort flying from Wuhan to Germany. Two patients were asymptomatic test positive; additionally virus isolation was achieved, indicating potential infectiousness.
	<i>Tracking studies</i>					
[4]	Huang et al. (2020)	Nanjing, China	4	Median	3-5 range	Follow-up tracing case study cluster of infection within a family demonstrating pre-symptomatic infection (n=10)
[9]	Rothe et al. (2020)	Germany	2	Median	1-3 range	Tracing case study of a cluster of infections whereby pre-symptomatic transmission occurred (n=3).
[29]	He et al. (2020)	Vietnam, Malaysia, Japan, China, Taiwan, USA, Singapore	2.3	Mean	95% CI, 0.8–3.0	Tracing paper infector-infectee pairs. Estimated from serial interval and incubation periods. N=77
[30]	Wei et al. (2020)	Singapore	2.5	Median	2-3 (IQR)	Tracing study investigating pre-symptomatic infections from primary cases to secondary cases in 7 clusters. N=8 primary cases. T3 estimated as the min. days between transmission period (TP) and primary case

						symptom onset, when TP straddled >1 day. Range: 2-6 days.
Modelling studies						
[32]	Peak et al. (2020)	Massachusetts	0.8 [estimate]	Mean	-0.29-1.98 95% CI*	Modelling paper estimated under two scenarios – a serial interval of 4.8 days or 7.5 days. Under scenario one, the model estimated a period of pre-symptomatic transmission (median: 0.71). * the lower range was fixed at zero as the model allowed for no pre-symptomatic infectious case.
[37]	Zhu et al. (2020)	Wuhan, China	1.0 [estimate]	Mean		Modelling paper. Model estimated point value – This is a model derived value
[14]	Davies et al. (2020) (a)	UK	2.4 [prior]	Mean		Modelling paper. Gamma distribution; k=5.
[15]	Davies et al. (2020) (b)	UK	1.5 [prior]	Mean		Modelling paper. Gamma distribution: k=4
[26,39]	Tuite et al. (2020a & b)	Canada	0.5, 1 [prior]	Fixed		Modelling paper. Fixed parameter within a deterministic model.
[72]	Ferguson et al. (2020)	UK	0.5 [prior]	Fixed		Modelling paper. Fixed parameter within a this model, whereby infectiousness was assumed to begin 12 hours become symptoms.
[31]	Tindale et al. (2020)	Tianjin, China, and Singapore	2.9-2.6 [estimate]	Mean	1.2-8.2 mean range, depending on early or late cases, or whether in Tianjin, Singapore	Statistical modelling study estimating period pre-symptomatic transmission inferred from estimates of serial interval and incubation periods for populations in Tianjin and Singapore (n=228).

781

782

783 **Table 3:** Reported infectious period (IP) for post-symptomatic cases (T5 parameter) from virological
 784 studies where serial diagnostic tests were undertaken to infer IP [onset to ≥ 2 tests]; tracking studies
 785 where IP is inferred from patient histories from onset to recovery or death; modelling studies where
 786 IP is reported as a prior (assumed parameter value) or an posterior estimate.

No.	Study	Location	Parameter (days)	Central tendency reported	Variation (days; inclus.)	Comment
<i>Virological studies</i>						
[73]	Cai et al. 2020 (a)	China	12	Median	6-22 range	Serial testing study of n=10 mild cases RT-PCR confirmed in children. IQR: 8-15 days
[74]	Cai et al. 2020 (b)	China	14	Median	9-19 (IQR)	Serial testing study with n=298 confirmed (RT-PCR) cases treated within hospital setting
[75]	Chen et al.(2020)	China	12	Max.		Single case study for a patient admitted to hospital where RT-PCR serial testing was undertaken. Patient had an additional positive test at day 17, but subsequently tested negative
[76]	Cheng et al. (2020)	China	21	Max.		Case study of single patient serially tested by RT-PCR
[7]	Hu et al. (2020)	China	12	Median	12-14 (IQR)	Serial testing study of patients who were first tested (qRT-PCR) when asymptomatic; this subset subsequently developed symptoms (n=5).
[42]	Kim et al. (2020)	Korea	15.5	Median	14-17 (range)	Serial testing of two confirmed cases via RT-PCR. Viral load highest during early phase of infection (day 3-5).
[43]	Kujawski et al. (2020)	USA	26	Max.		Serial testing of two confirmed cases via RT-PCR. Mild to moderate symptoms.
[77]	Lee et al. (2020)	Taiwan	20	Max.		Serial testing (RT-PCR) of a single patient hospitalised presenting with pneumonia
[44]	Lim et al. (2020)	South Korea	16	Max.		Serial testing (RT-PCR) of a single patient hospitalised presenting with pneumonia. Two clear tests day 11, virus

						detectable again up to day 16.
[78]	Ling et al. (2020)	China	9.5	Median	2-22 (range)	Serial testing of two confirmed cases via RT-PCR. n=66. IQR: 6-11 days, oropharyngeal sampling. Mix of adult and children.
[79]	Liu et al. (2020)	China	11	Median	7-18 range	Serial testing of two confirmed cases via RT-PCR. n=10. 10-13 (IQR); adults, mild, moderate, and severe cases.
[45]	Marchand-Senéca et al. (2020)	Canada	23	Max		Serial testing (RT-PCR) of a single patient hospitalised presenting with pneumonia.
[3]	Pan et al. (2020)	China	10	Median	8-12 range	Serial testing (RT-PCR) of two patients hospitalised. Viral loads peaked days 5-6 post-onset.
[80]	Qu et al. (2020)	China	22	Max		Serial testing (RT-PCR) of a single patient hospitalised
[46]	Tan et al. (2020)	Vietnam	16	Max		Serial testing (RT-PCR) of a single patient hospitalised; throat sample.
[47]	Thevarajan et al. (2020)	Australia	7	Max		Serial testing (RT-PCR) of a single patient hospitalised; throat sample. Highest viral load on first test at day 4 in nasopharyngeal; day 6 for sputum.
[69]	Xing et al. (2020)	China	14	Median		Serial testing (RT-PCR) of a three (children) patients hospitalised. Mild-moderate infecting. Positive viral samples from faeces up to 4 weeks post-symptoms.
[52]	Young et al. (2020)	Singapore	12.5	Median		Serial testing (RT-PCR) of 18 patients hospitalised. Adults. Viral load peaked over testing series at day 4 since onset.
[81]	Yuan et al. (2020)	China	6	Median	4-10 (IQR)	Serial testing (RT-PCR) of 25 patients hospitalised. Children and adults. "Non-severe" cases.
[71]	Zhou et al. (2020)	China	20	Median	16-23 IQR	Serial testing (RT-PCR) of 191 patients hospitalised in two hospitals. Adults. 54 died. Survivors (n=137); Median (IQR) 20.0 days (17.0–24.0); Non-survivors

						(n=54); Median (IQR) 18.5 days (15.0–22.0); Shedding continued until death. Inferred shedding period; 8-37 days.
[82]	Chen J. et al. (2020)	China	11	Median	10-12 (95%CI)	Serial testing (RT-PCR) of 242 patients hospitalised. Adults. 90% mild/asymptomatic; 10% severe/critical.
[60]	Fang et al. (2020)	China	15.7	Mean	6.7 (sd)	Serial testing (RT-PCR) of 24 non-ICU patients hospitalised. Adults. Nasal samples.
[60]	Fang et al. (2020)	China	22.3	Mean	3.6 (sd)	Serial testing (RT-PCR) of 8 ICU patients hospitalised. Adults. Nasal samples.
[57]	Hill et al. (2020)	Scotland	9	Max.		Serial testing (RT-PCR) of a single patient (adult) hospitalised; nasal sample [throat sample: 6 days]. Mild.
[83]	Le et al. (2020)	Vietnam	12	Max.		Serial testing (RT-PCR) of a single patient (infant) hospitalised. Mild.
[58]	Liu et al. (2020)	China	10	Max.		Serial testing (RT-PCR) of a patients hospitalised. Adults. Mixed Mild/severe cases. N=76. 90% “early viral clearance” within 10days
[84]	Qiu et al. (2020)	China	10	Mean	7-22 range	Serial testing (RT-PCR) of a patients hospitalised. Children. N=36. Mild and moderate cases.
[59]	To et al. (2020)	Hong Kong	25	Max.		Serial testing (RT-PCR) of a patients hospitalised. N=7. Seven patients reported viral detection >20 days; viral load peaked during first week post-onset of symptoms.
[85]	Wu et al.	China	16.1	Mean	6.7 (sd)	Serial testing (RT-PCR) of patients hospitalised. Adults. N=74. Severe and non-severe cases.
Tracking studies						
[31]	Tindale et al. (2020)	Singapore	18	Median	9-33 range	Time from onset to discharge; range 9-33; n=53
[35,36]	Kraemer et al. (2020a);	Various	19	Median	3-37 range	Time from onset to discharge; Range: 3-37;

	[later published as: Xu et al. 2020]					n=70
[34]	Linton et al. (2020)	Wuhan, China	13	Median	6-41 range	Time from onset to death; range 6-41
[35,36]	Kraemer et al. (2020b)	Japan and China	19.25	Mean	12-24 range	Time from onset to death; n=4
[49,50]	Wölfel et al. (2020)	Germany	3-8 days	absolute	3-8 range	Tracked infection in mild cases in Germany, undertaking viral isolation studies to assess active replication across a number of samples sites (upper respiratory tract, blood, urine, faeces) over the duration of infection. 5% isolation success was achieved up to 9.78 (95% CI: 8.45-21.78) days post onset; n=9

787

788

789 **Table 4:** Reported infectious period (IP) for symptomatic cases (T3+T5 parameter) from virological
 790 studies where serial diagnostic tests were undertaken to infer IP [exposure to ≥ 2 tests]; tracking
 791 studies where IP is inferred from patient histories from onset to recovery or death; modelling studies
 792 where IP is reported as a prior (assumed parameter value) or an posterior estimate.

No.	Study	Location	Parameter (days)	Central tendency reported	Variation (days; inclus.)	Comment
Tracking studies						
[29]	He et al. (2020)	Vietnam, Malaysia, Japan, China, Taiwan, USA, Singapore	9.3 days	Mean	7.8-10 (95%CI*)	The paper reported on 77 infector-infectee pairs which were sequential/serially tested, using publicly available data. Viral dynamics (Guangzhou, China; N=94) interpreted by the authors suggested an infectious period starting 2.3 (95% CI, 0.8–3.0 days) days prior to symptoms, peaking 0.7 days (95% CI, -0.2–2.0 days), continuing up to 7 days from onset. * CI from pre-symptom infectious period only.
[8]	Ma et al. (2020)	Various	~5 days	Median	Range 0-24	The authors estimated the infectious period as latent minus the serial interval, using a dataset of 1155 cases. Range 0-24; IQR: 2-9; calculated from data presented within the paper.
Modelling studies						
[27]	Li et al. (2020)	China	3.45 days [posterior estimated from model for documented cases]	median	95%CI for the mean: 3.19, 3.72	Mathematical model. Priors for <u>mean</u> documented infectious period was a flat [uniform] distribution 2-5. 'Documented' cases were defined as those severe enough to be confirmed. This corraling of the infectious period relative to other


						studies should take into account that the distribution is used for the central tendency, not the whole distribution.
[26,39]	Tuite et al. (a, b) (2020)	Canada	6-6.5 days [prior; fixed parameter within a deterministic model]	Fixed parameter		Mathematical model [deterministic], with a fixed parameter estimate of 6.5 days (a) and 6 days (b), respectively. Important to note that duration for 'mild' was equal to severe cases.
[86]	Lourenco et al. (2020)	UK	~3-5 days [posterior; approximate depending on scenario tested]	mean	95%ci of 3-6 days	Mathematical model. The <u>prior</u> used was given a Gaussian distribution (normal curve); mean 4.5; SD 1; approximate 95%ci of 3-6 days. The reported posterior of this parameter was presented graphically and depended on R0 and proportion at risk. Depending on the scenarios tested, mean duration of infectiousness appeared to vary from 3-5 days.
[37]	Zhu et al. (2020)	Wuhan, China	12.5 days [posterior estimated from model]	Mean	11.4 variance	Mathematical model. The parameter was estimated using a Weibull distribution. The prior for this parameter was 10 days. The posterior variance around the mean was 11.4, and therefore the distribution had a long tail. This study was a modelling [SEIR extended model].
[15]	Davies et al. (b) (2020)	UK	7 days [Prior]	Mean		Model with asymptomatic infection compartment. Modelled with a

						gamma distribution, beta 1.4; alpha 5. Despite, the subclinical aspect of this parameter, it could be considered analogous to total infectious period without intervention.
[14]	Davies et al. (b) (2020)	UK	5 days [Prior]	Mean		Model with asymptomatic infection compartment. Modelled with a gamma distribution, $k=4$. Authors: "Assumed to be the same duration as total infectious period for clinical cases, including preclinical transmission"
[38]	Piccolomini and Zama (2020)	Italy	20 days [Prior]	Fixed		Parameter estimate assumed for the infectious period within an SEIRD model, fitted to data from the epidemic in Italy.

793

794

795 **Supplementary material:**




796

797 **Figure S1:** Conceptual model of the key temporal parameters impacting COVID-19 infection
 798 progression over time. T1: Latent period; T2: Asymptomatic infectious period; T3: Pre-symptomatic
 799 infectious period; T4: Symptom onset to diagnosis [self-isolation] or hospitalisation; T5: Symptom
 800 onset to removed [death or recovery]

801

802 **Figure S2:** Cumulative infectiousness (% of total infectiousness) based on infector-infectee pair data
 803 in the paper by Cheng et al. 2020. The accumulation curve is based on a gamma density function,
 804 coupled with a probability function to capture the maximal probability if exposed to a primary case.



805

806 **Reference:**

807 Cheng, H.Y., Jian, S.W., Liu, D.P., Ng, T.C., Huang, W.T. and Lin, H.H., 2020. High transmissibility of
808 COVID-19 near symptom onset. *medRxiv*.